Addition of Talicia by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization is an important expansion of coverage for California patients and continues to increase Talicia’s overall unrestricted coverage®
Coverage commenced for two million patients in Medi-Cal’s FFS plan on October 1st, 2021
Talicia is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies
H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population®
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 6, 2021 — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Medi-Cal – California’s Medicaid Health Care program covering two million patients – has added Talicia (omeprazole magnesium, amoxicillin and rifabutin)®1 to its Contract Drug List (CDL) for H. pylori treatment, with no prior authorization required, effective October 1, 2021.
Coverage for Talicia commenced for two million patients in Medi-Cal’s California FFS plan on October 1, 2021.
“Medi-Cal’s addition of Talicia with no prior authorization required is an important step in Talicia’s continuing growth and we are pleased that it will be made available to Medi-Cal’s 2 million FFS lives,” said Rick Scruggs, RedHill’s Chief Commercial Officer. “There is growing recognition of the need to employ effective, first-line therapy against H. pylori infections that does not rely on clarithromycin and that patients can tolerate well and adhere to over 14 days of therapy. Talicia meets those criteria.”
